@medresearchnews Tag

MedicalResearch.com Interview with: [caption id="attachment_70205" align="alignleft" width="125"]Shannon D. DonofryBehavioral Scientist B.A.Sc. in psychology/neuroscience University of Pittsburgh-Pittsburgh Campus; Ph.D, University of Pittsburgh-Pittsburgh Campus Dr. Donofry[/caption] Shannon D. Donofry Ph.D. Behavioral Scientist B.A.Sc. in psychology/neuroscience University of Pittsburgh-Pittsburgh Campus; Ph.D, University of Pittsburgh-Pittsburgh Campus   [caption id="attachment_70207" align="alignleft" width="125"]Katherine M. Rancaño, Ph.DAssociate Policy Researcher RAND Dr. Rancaño[/caption] Katherine M. Rancaño, Ph.D Associate Policy Researcher RAND   MedicalResearch.com: What is the background for this study? Response: GLP-1 medications were first used to help people with diabetes manage their blood sugar. Lately, they’ve become popular for helping people lose weight, too. Because of this, a lot more people have started using them. In our study, we asked over 8,000 adults from across the country about their use of GLP-1 medications and any side effects they had.

MedicalResearch.com Interview with: [caption id="attachment_70179" align="alignleft" width="220"]Emily G. McDonald MD MSc (Epi) FRCPCScientist | Research Institute of the McGill University Health Centre Associate Professor of Medicine | General Internal Medicine | McGill University Health Centre Associate Chair of Quality and Safety | Department of Medicine | McGill University Director | Canadian Medication Appropriateness and Deprescribing Network Centre for Outcomes Research and Evaluation (CORE) Montreal, QC Dr. McDonald[/caption] Emily G. McDonald MD MSc (Epi) FRCPC Scientist | Research Institute of the McGill University Health Centre Associate Professor of Medicine | General Internal Medicine | McGill University Health Centre Associate Chair of Quality and Safety | Department of Medicine | McGill University Director | Canadian Medication Appropriateness and Deprescribing Network Centre for Outcomes Research and Evaluation (CORE) Montreal, QC https://www.medsafer.org/ https://www.deprescribingnetwork.ca/   MedicalResearch.com: What is the background for this study? What are the main findings? Response: Polypharmacy (taking multiple medications) is common among older adults and can lead to serious side effects like memory problems, falls, fractures, and hospitalization. Deprescribing (the process of stopping some medications that may no longer be beneficial or where the harms outweigh the benefits) is a great solution. This study found that an electronic tool to support prescribers increased deprescribing more than 3 times compared to usual care without the software support.

MedicalResearch.com Interview with: [caption id="attachment_70015" align="alignleft" width="152"]Prof. Yonatan M. Kupchik PhD andLiran Levi, PhD student Faculty of Medicine at Hebrew University Prof. Kupchik[/caption] Prof. Yonatan M. Kupchik PhD and [caption id="attachment_70017" align="alignleft" width="138"]Liran Levi L. Levi[/caption] Liran Levi, PhD student Faculty of Medicine at Hebrew University MedicalResearch.com: What is the background for this study? Response: Motivated behavior is driven by a group of brain regions called collectively the reward system. This neural system is at the heart of every decision we make about our actions - it integrates information about the world and decides whether to perform a behavior or not based on the predicted reward/benefit. The key molecule in this process is dopamine - whenever we perform a behavior that provides a reward dopamine is released in the reward system and reinforces this behavior. Drugs of abuse exploit this system - they cause abnormally high levels of dopamine, and thus force the reward system to seek drugs constantly, even after prolonged withdrawal. From a neurobiological perspective, that is how we view substance dependence - the reward system drives people to seek for the reward.

MedicalResearch.com Interview with: [caption id="attachment_69623" align="alignleft" width="180"]Ding Ding (Melody), Ph.D., MPHProfessor of Public Health/NHMRC Emerging Leader Fellow Prevention Research Collaboration Sydney School of Public Health Faculty of Medicine and Health The University of Sydney Prof. Ding[/caption] Ding Ding (Melody), Ph.D., MPH Professor of Public Health/NHMRC Emerging Leader Fellow Prevention Research Collaboration Sydney School of Public Health Faculty of Medicine and Health The University of Sydney MedicalResearch.com: What is the background for this study? Response: While we already know physical activity benefits health, public guidelines focus on total minutes of moderate-to-vigorous activity per week, usually 150 to 300 minutes. However, many people track their activity by steps, a simple and accessible metric, but the popular 10,000-steps-a-day goal isn’t actually based on solid evidence. Our review sought to clarify how many steps per day are linked to meaningful health benefits.

MedicalResearch.com Interview with: [caption id="attachment_69504" align="alignleft" width="200"]Gabriele Campanella, PhDAssistant Professor
Windreich Department of Artificial Intelligence and Human Health
Icahn School of Medicine at Mount Sinai Dr. Campanella[/caption] Gabriele Campanella, PhD Assistant Professor Windreich Department of Artificial Intelligence and Human Health Icahn School of Medicine at Mount Sinai MedicalResearch.com: What is the background for this study? Response: Lung cancer is the most lethal cancer in the US. Lung adenocarcinoma (LUAD) is the most common form of lung cancer with an incidence of over 100k per year in the US. EGFR mutations are common driver mutations in LUAD, and importantly, these mutations can be targeted by TKI therapy, which has high response rates. Because of this, EGFR testing via NGS (Next Generation Sequencing) is considered mandatory by guidelines for any LUAD diagnosis. In high-resource settings, rapid EGFR testing is done while waiting for confirmation via NGS. This is because NGS takes about 2 weeks on average, while the rapid testing has a median TAT of 2 days. Early treatment decisions could be made based on the rapid test results. Rapid tests have some important drawbacks, most notably, it exhausts tissue. In lung cancer, tissue is scarce in the first place, and up to 25% of cases, after rapid testing there is not enough tissue for NGS. In those circumstances, patients have to be biopsied again, which adds unnecessary risk for the patient. Even worse, in some cases, the NGS is never done. A non-tissue-exhaustive computational biomarker could be used instead of the tissue-based rapid test.

[caption id="attachment_69481" align="aligncenter" width="500"]computer-literature-view-ai Pexels image[/caption] Medical research is at the heart of clinical advancement. Whether evaluating the safety of new treatments or analyzing trends across patient populations, the integrity and efficiency of research practices have direct implications on healthcare delivery. Among the most labor-intensive tasks in medical research are literature reviews and meta-analyses—two foundational methodologies that aggregate findings from multiple studies to draw broader, evidence-based conclusions. With the volume of published medical literature increasing exponentially each year, traditional methods of reviewing research have become less sustainable. Today, artificial intelligence (AI) is beginning to play a transformative role in this process, offering ways to streamline literature searches, extract relevant data, reduce bias, and increase reproducibility. AI isn't replacing researchers—it’s empowering them with tools that can manage scale, speed, and complexity in ways manual methods cannot match.

[caption id="attachment_69467" align="aligncenter" width="500"]importance-data-management-clinical-trials Photo by Christina Morillo[/caption] Every clinical trial produces mountains of data. From patient enrollment logs and lab results to adverse event reports and protocol deviations, clinical data is the backbone of every decision made during drug or device development. Yet, collecting data is only the beginning — it’s how that data is managed, validated, and interpreted that determines a study’s success. In the age of decentralized trials, real-time analytics, and global regulatory oversight, the importance of reliable clinical data management can’t be overstated. High-quality data doesn’t just support regulatory submissions — it protects patient safety, ensures compliance, and strengthens confidence in results.

Why Is Clinical Data Management No Longer Just a Technical Task?

Gone are the days when data management was treated as an afterthought or a purely technical role. Today, it’s central to trial strategy. From the very beginning of a study, data management professionals are involved in shaping case report forms (CRFs), planning how endpoints will be measured, and ensuring systems are in place to capture data accurately and securely. This shift in thinking is due to the increasing complexity of trial protocols, the rise in remote data capture tools, and the growing pressure from regulators for traceable, auditable datasets. Sponsors and CROs alike are realizing that data management is no longer an isolated function — it’s the foundation of trial integrity.

What Does a Modern Clinical Trial Data Management Service Include?

A robust clinical trial data management service goes far beyond database design. It encompasses an ecosystem of systems, people, and processes designed to ensure that every data point collected is clean, consistent, and ready for analysis. Typical services include:
  • CRF design tailored to protocol endpoints
  • Electronic Data Capture (EDC) system configuration
  • Real-time data monitoring and discrepancy resolution
  • Medical coding using standard dictionaries (e.g., MedDRA, WHO Drug)
  • Query management and investigator communication
  • Data cleaning, validation, and database lock support
The goal is simple: to transform complex, multi-source data into a reliable and statistically sound dataset that regulators can trust — and that sponsors can use to make decisions.

MedicalResearch.com Interview with: [caption id="attachment_69366" align="alignleft" width="240"]Hideyuki Saya, MD, PhDDirector, Oncology Innovation Center Fujita Health University Toyoake, JAPAN Dr. Hideyuki Saya, MD, PhD[/caption] Hideyuki Saya, MD, PhD Director, Oncology Innovation Center Fujita Health University Toyoake, Japan MedicalResearch.com: What is the background for this study? Response: Benzaldehyde, a simple aromatic compound found in the natural aroma of almonds and apricots, has long been reported to have anticancer activity, with clinical trials even conducted in Japan in the 1980s. However, the molecular mechanism underlying its anticancer effect has remained unclear for decades. Our study was initiated by Dr. Jun Saito, whose father was one of the original researchers studying benzaldehyde. Driven by a personal motivation to clarify the scientific basis of this compound’s effect, Dr. Saito spent over a decade in our lab to finally uncover its mechanism of action.

MedicalResearch.com Interview with: [caption id="attachment_69251" align="alignleft" width="156"]Tomas Kirchhoff, PhD (corresponding author)Associate ProfessorLaura and Isaac Perlmutter Cancer Center New York University School of Medicine Dr. Kirchhoff[/caption] Tomas Kirchhoff, PhD (corresponding author) Associate ProfessorLaura and Isaac Perlmutter Cancer Center New York University School of Medicine Robert Ferguson PhD Senior Scientist at NYU Langone Medical Center Kelsey Monson, PhD Immuno-Oncology Postdoctoral Researcher Icahn School of Medicine at Mount Sinai MedicalResearch.com: What is the background for this study? Would you briefly explain how mitochondrial DNA differs from chromosomal DNA? TK: Immune checkpoint blockade has changed the way we treat several cancers, including advanced melanoma. Before these therapies, the treatment options were very limited, but now more than half of patients experience significant tumor shrinkage or disease control. KRM: Despite these advances, many patients still do not respond to treatment. One of the main challenges in cancer medicine today is to find ways to predict which patients will benefit from these therapies before treatment begins. This approach is key to personalizing care and improving outcomes. RF: Mitochondria are small structures inside our cells that produce the energy needed for cells to function. Unlike most of our DNA, mitochondrial DNA is inherited only from the mother. Scientists can categorize this mitochondrial DNA into groups called haplogroups, based on unique variations in the genetic code. These haplogroups can provide insight into how cells produce energy and may affect a person’s health or response to cancer treatment.

[caption id="attachment_68652" align="aligncenter" width="500"]laboratories-lab-safety-osha Photo by Artem Podrez[/caption] In clinical and research settings, precision and control are everything. Whether conducting patient care, handling biological specimens or operating within a sterile lab environment, every person involved must operate with safety in mind. While much attention is often given to technical procedures and scientific outcomes, the foundation that makes these environments functional is a shared understanding of workplace safety. This is where an OSHA compliance certification becomes essential. Medical and research facilities are not immune to hazards. Everyday, professionals work with chemical agents, compressed gases, sharps lab equipment and occasionally volatile substances. These environments demand more than professional skill; they require a framework that reinforces how to prevent incidents before they occur. OSHA, the Occupational Safety and Health Administration, provides exactly that framework through its compliance standards and training programs.

MedicalResearch.com Interview with: Jingzhen Ginger Yang, PhD, MPH Principal Investigator at the Center for Injury Research and Policy Abigail Wexner Research Institute at Nationwide Children’s Hospital Professor of Pediatrics at The Ohio State University College of Medicine with a courtesy appointment in the Department of Epidemiolog in The Ohio State University College of Public HealthJingzhen Ginger Yang, PhD, MPH Principal Investigator at the Center for Injury Research and Policy Abigail Wexner Research Institute at Nationwide Children’s Hospital Professor of Pediatrics at The Ohio State University College of Medicine with a courtesy appointment in the Department of Epidemiolog in The Ohio State University College of Public Health MedicalResearch.com: What is the background for this study? Response: Motor vehicle crashes are the leading cause of death for U.S. teens. Newer vehicles and driver assistance technologies show promise in reducing crashes and injury severities. Our study found that driving vehicles 6-15 years old had a 19% greater risk of driver death in fatal crashes, and driving vehicles older than 15 years had a 31% greater risk, both compared to driving vehicles 5 years old or newer, regardless of driver age. Additionally, each driver assistance technology already present in vehicles was associated with a 6% reduction in the risk of driver death in fatal crashes.

MedicalResearch.com Interview with: [caption id="attachment_68399" align="alignleft" width="150"]Ashley Robinson, MD, lead authorSecond-year internal medicine resident
Advocate Lutheran General Hospital Dr. Robinson[/caption] Ashley Robinson, MD, lead author Second-year internal medicine resident Advocate Lutheran General Hospital MedicalResearch.com: What is the background for this study? Response: Briefly, anal cancer makes up around 1% of gastrointestinal cancers and more than 90% of all anal cancers are caused by chronic human papillomavirus or HPV infections. In previous research, it has been noted that women over the age of 65 have rates that were increasing more than other groups and myself along with my colleagues and the principal investigator of this project, Dr. Eli Ehrenpreis, wanted to further characterize these findings, looking into more specific details of these previously noted trends. Using data from a public database ran by the National Cancer Institute called the Surveillance, Epidemiology and End Results program, also known as SEER, and their statistical analysis software, SEER*Stat, we analyzed anal cancer incidence trends, looking at differences between sex, age, and ethnicity in order to further identify specific groups that have more rapidly increasing rates than others.

[caption id="attachment_68344" align="alignleft" width="200"]MedicalResearch.com Interview with:Dr. Katilyn Gernhard Dr. Gernhard[/caption] MedicalResearch.com Interview with: Dr. Katilyn Gernhard DO Internal Medicine Resident Allegheny Health Network Pittsburgh MedicalResearch.com: What is the background for this study? Response: The background for this study is the steadily rising prevalence of obesity in the United States, which has been accompanied by an increase in related comorbid conditions, including Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD). Bariatric surgery and GLP-1 receptor agonists are two commonly used treatment options to address obesity and its associated complications. While both have demonstrated benefits in weight loss and metabolic improvement, there has been limited direct comparison of their effectiveness specifically in patients with MASLD. Our study aimed to address this gap by comparing clinical outcomes in patients with MASLD treated with GLP-1 receptor agonists versus those treated with bariatric surgery.

MedicalResearch.com Interview with: [caption id="attachment_68373" align="alignleft" width="160"]Dr. Simon Steenson PhDPostdoctoral Research Associate
Department of Nutritional Sciences
King’s College London Dr. Steenson[/caption] Dr. Simon Steenson PhD Postdoctoral Research Associate Department of Nutritional Sciences King’s College London MedicalResearch.com: What is the background for this study? Response: Chronic constipation is something that can be embarrassing, but it affects 1 in 10 people globally. It has a big impact on people’s quality of life and treating constipation has substantial costs for the healthcare system. Dried fruits are recommended for managing constipation, but there are very few studies that have actually tested whether following this advice is helpful. To fill this gap in our knowledge, we completed the largest clinical trial to date to see whether dried fruits and fruit juices could benefit constipation symptoms. 

MedicalResearch.com Interview with: [caption id="attachment_68341" align="alignleft" width="125"]Douglas Corley, MD, PhD  Chief Research Officer, The Permanente Medical Group Kaiser Permanente, Northern California Dr. Corley[/caption] Douglas Corley, MD, PhD Chief Research Officer, The Permanente Medical Group Kaiser Permanente, Northern California MedicalResearch.com: What is the background for this study? Response: Kaiser Permanente Northern California (KPNC) is an integrated health care system that designs and implements population-based programs that support cancer prevention and early detection. In 2006, KPNC began to implement a comprehensive colorectal cancer screening program with the goal of increasing member screening rates, preventing colorectal cancer through polyp removal, and reducing cancer mortality. The initiative identifies whether screening-eligible KPNC members are up to date with their colorectal cancer screening test by either a colonoscopy or by stool-based tests, such as a fecal immunochemical testing (FIT) kit. If they are not up to date with screening, it mails them a FIT kit for at-home testing. Members can also choose other options for colorectal cancer screening, such as a colonoscopy, through their physician.

[caption id="attachment_68201" align="alignleft" width="150"]dr_aditya_shreenivas Dr. Shreenivas[/caption] MedicalResearch.com Interview with: Aditya Shreenivas M.D.,  M.S. Assistant Professor Department of Medical Oncology & Therapeutics Research City of Hope MedicalResearch.com: What is the background for this study? Response: Nasopharyngeal carcinoma (NPC) is a highly aggressive tumor of the head and neck region with a distinct geographical distribution, with incidence rates as high as 30 per 100,000 in endemic regions like Asia and North Africa but less than 1 per 100,000 worldwide. Despite comprehensive curative intent therapy, up to 30% of patients with advanced NPC experience treatment failure, primarily due to recurrence and/or metastasis. This high mortality rate highlighted the urgent need for effective treatments. Clinical trials (JUPITER-02, CAPTAIN-1st, and RATIONALE-309) showed improved progression-free survival by adding anti-PD-1 antibodies to chemotherapy for first-line treatment of recurrent or metastatic NPC. However, these studies were conducted exclusively in Asian populations. Penpulimab is a humanized anti-PD-1 antibody that's unique because it is a  IgG1 subtype with a modified Fc segment. This structure potentially improves efficacy and safety compared to other anti-PD-1 drugs through lower immune-related adverse events.

MedicalResearch.com with: [caption id="attachment_67952" align="alignleft" width="125"]Dr. David Klonoff MDMedical Director of the Dorothy L. and James E. Frank Diabetes Research Institute of Mills-Peninsula Medical Center Clinical Professor of Medicine at UCSF Dr. Klonoff[/caption] Dr. David Klonoff MD Medical Director of the Dorothy L. and James E. Frank Diabetes Research Institute of Mills-Peninsula Medical Center Clinical Professor of Medicine at UCSF   MedicalResearch.com: What is the background for this the FITTER Forward expert recommendations?
  • The focus of healthcare professionals (HCPs) tends to be primarily on the drug and overall treatment, while the administration of insulin and other peptide medications—which can play a critical role in outcomes—is often overlooked. The Fitter Forward group, consisting of 16 diabetes experts from 13 countries, decided to update a previous set of recommendations that was almost a decade old, with newly published evidence and materials. This new report, published in the April 2025 edition of Mayo Clinic Proceedings, highlights recent advances in needle technology, the physiology of insulin injections, and proper injection techniques.

MedicalResearch.com Interview with: [caption id="attachment_67865" align="alignleft" width="200"]Sam (Seyedmehdi) Payabvash, MD Associate Professor of Radiology  Columbia University Medical Center Dr. Payabvash[/caption] Sam (Seyedmehdi) Payabvash, MD Associate Professor of Radiology Columbia University Medical Center MedicalResearch.com: What is the background for this study? Response: Prenatal marijuana use is on the rise, largely due to increasing legalization and shifting public perception of its safety during pregnancy. Although prior studies have linked prenatal marijuana exposure to adverse neonatal and behavioral outcomes, the long-term neurodevelopmental effects, especially as assessed through advanced neuroimaging techniques, remain underexplored.

MedicalResearch.com Interview with: [caption id="attachment_67888" align="alignleft" width="200"]Prof. Hermona SoreqThe Edmond and Lily Safra Center for Brain Sciences (ELSC) and
The Alexander Silberman Institute of Life Science
at the Hebrew University Hermona Soreq, lab, students, collaboration[/caption] Prof. Hermona Soreq The Edmond and Lily Safra Center for Brain Sciences (ELSC) and The Alexander Silberman Institute of Life Science at the Hebrew University MedicalResearch.com: What is the background for this study? What are tRFs and how do they impact neurodegeneration?

Response:   tRFs: The molecular SOS of early life stress

If you remember your high school biology classes, you might remember that tRNAs are molecules that help assemble proteins based on encoding amino acids. In recent years, scientists discovered that when these molecules break down it’s not merely cellular garbage – it can be gold. Specifically, tRNAs can be sliced into short pieces, called tRNA fragments (or tRFs), which act like little regulators, switching translation on and off in ways we’re still trying to understand. Think of a tRNA as a Swiss army knife. It has structure, function, and folds on itself. But under certain conditions - like stress - it's chopped up into smaller pieces, each with a distinct signal. These fragments aren't random junk; they’re more like emergency messages, scattered through the bloodstream, reflecting the body’s internal state. That idea - of tRFs as biological SOS signals - led us to wonder: could these fragments tell us what the fetus experiences in utero? Could they show us, in molecular form, the impact of maternal psychosocial stress?

[caption id="attachment_67701" align="alignleft" width="155"]parita-ray.png Parita K. Ray[/caption]

Parita K. Ray

Medical Student

Department of Medical Education

Geisinger College of Health Sciences

Scranton, PA 18509

 

MedicalResearch.com: What is the background for this study?

  • Citalopram and escitalopram are two of the most commonly prescribed antidepressants in the U.S. and are widely used for treating major depressive disorder (MDD) and generalized anxiety disorder (GAD), along with various off-label indications. While both medications share similar mechanisms of action, escitalopram was introduced as a purified version of citalopram’s active enantiomer. Despite little evidence showing a clear superiority of escitalopram over citalopram in efficacy or tolerability, prescribing trends appear to favor escitalopram, raising concerns about "evergreening"—a practice where pharmaceutical companies promote newer formulations of existing drugs to extend market exclusivity. Prior research has shown variations in the prescription rates of psychotropic medications across states and within specific populations, particularly among Medicaid and Medicare patients. However, little is known about the long-term prescribing patterns of citalopram versus escitalopram in these populations and whether these trends reflect potential evergreening practices.

[caption id="attachment_67204" align="alignleft" width="200"] Prof. El GHOCH[/caption] MedicalResearch.com Interview with: Prof. Marwan EL GHOCH Professore Associato in Scienza dell'Alimentazione e Tecniche Dietetiche Applicate MEDS-08/C Dipartimento di Scienze Biomediche, Metaboliche e Neuroscienze Università di Modena e Reggio Emilia Modena, 41125, Italy MedicalResearch.com: What is the background for this study? Response: Body mass index (BMI) is an easy-to-use tool to determine an individual’s by classifying him/her as having normal weight, overweight, or obesity, and this is based on universal cut-off points suggested by the World Health Organization (WHO) for all age groups. Not taking into account the potential changes that may occur to body composition compartments during the individual’s lifespan. In fact, little is still known about this topic in people with overweight and obesity. For this reason our study aimed to compare the body composition compartments between three different age groups (young, middle-age, and older adults), adopting a design that matched these 3 age groups by BMI.

[caption id="attachment_67338" align="aligncenter" width="500"]health-care-inequalities Photo by Tessy Agbonome[/caption]   Healthcare inequality remains one of the most pressing global challenges, affecting billions of people worldwide. Despite advancements in medical science and healthcare infrastructure, access to quality healthcare services remains unequal across different regions, socioeconomic groups, and communities. Disparities in healthcare access, affordability, and outcomes persist due to factors such as income level, geographic location, race, gender, and social status. However, technology has emerged as a powerful tool in bridging these gaps and democratizing healthcare. From telemedicine and wearable devices to artificial intelligence (AI) and big data, innovative technologies are transforming the healthcare landscape and making healthcare more accessible, affordable, and efficient. Healthcare software developers play a crucial role in this transformation, creating the digital platforms, applications, and tools that enable these technological advancements to reach a wider audience.

clinical-trials-faster-research-outcomes Clinical trials are essential for advancing medical science and developing new treatments. However, the process can often be slow and cumbersome, delaying the delivery of innovative therapies to patients in need. Emerging technologies are transforming this landscape, providing tools that make clinical trials more efficient and effective. As you explore the world of clinical trials, understanding the importance of efficient tools becomes paramount. These tools significantly accelerate clinical trial timelines, ensuring quicker access to vital medical interventions. The healthcare industry is witnessing a rapid evolution in how research is conducted, with technology playing a pivotal role in this transformation. Platforms like Patiro are instrumental in this shift, offering innovative ways to connect qualified patients with clinical trials.

The Impact of Technology on Clinical Trials

Technology is reshaping the way clinical trials are conducted, primarily by reducing enrollment delays. This crucial phase often poses significant challenges due to stringent criteria and the necessity for a diverse pool of participants. With advanced platforms leveraging data analytics and AI-driven solutions, researchers can swiftly identify and recruit suitable candidates. This expedites the process and enhances the quality of research outcomes by ensuring a representative sample. The integration of digital tools has further enabled remote monitoring and virtual trials, reducing geographical barriers that traditionally hindered participant enrollment. This shift broadens access and allows continuous data collection in real-time, increasing accuracy and reliability. The time saved in these processes directly contributes to faster trial completion and quicker dissemination of results. In addition to enrollment efficiencies, technological innovations facilitate better data management throughout the trial phases. Automation in data entry and processing minimizes human error, maintaining high standards of accuracy and compliance. Consequently, this fosters a more streamlined workflow, significantly cutting down on administrative burdens faced by research teams. Machine learning algorithms have revolutionized patient matching and protocol optimization, reducing the time spent on manual screening processes by up to 60%. These intelligent systems can analyze vast amounts of electronic health records, identifying potential participants who meet specific trial criteria within minutes rather than weeks. Additionally, predictive analytics help researchers anticipate and address potential bottlenecks before they impact trial timelines, ensuring smoother execution throughout the study lifecycle.

[caption id="attachment_67077" align="aligncenter" width="500"]Technology Is Transforming Healthcare.png Source[/caption] Technology is no longer a futuristic concept in healthcare — it's the present reality, reshaping everything from patient care to administrative tasks. This rapid evolution creates both challenges and unprecedented opportunities for those in healthcare careers. Understanding how technology impacts these roles is crucial for anyone looking to thrive in this dynamic field.

The Rise of the Machines? How Automation Is Reshaping Traditional Roles

Automation is changing the landscape, impacting tasks previously considered exclusively human. As a result, many healthcare jobs are in danger of going extinct. How are roles adapting?

The Digitalization of Healthcare Administration

Gone are the days of endless paper files and manual data entry. Electronic Health Records (EHRs) are now standard, streamlining workflows and making patient information readily accessible. This shift requires healthcare administrators to be tech-savvy, adept at managing digital systems and ensuring data security. Skills like data analysis and cybersecurity are now highly valued in administrative roles. Tasks like scheduling, billing, and insurance claims are increasingly automated, freeing up staff to focus on patient interaction and complex problem-solving.

MedicalResearch.com Interview with: [caption id="attachment_67040" align="alignleft" width="201"]Ricki S. Carroll, MDComplex Care and Palliative Care Physician, Skeletal Dysplasia and Palliative Care Teams Nemours Children’s Hospital Wilmington, Delaware Dr. Carroll[/caption] Ricki S. Carroll, MD Complex Care and Palliative Care Physician, Skeletal Dysplasia and Palliative Care Teams Nemours Children’s Hospital Wilmington, Delaware MedicalResearch.com: What is the background for this study? Response: Individuals with Osteogenesis imperfecta (OI) are often classified into one of four subtypes: type I (mild/nondeforming), type II (perinatal lethal), type III (severe/progressively deforming) and type IV (moderately deforming); however, this classification system continues to evolve with increasing knowledge (Sillence, 1979; Van Dyke & Sillence, 2014). Those with a mild phenotype are often diagnosed postnatally or in the pediatric setting after experiencing multiple unexplained fractures. Concerns for moderate to severely presenting OI are often noted in utero when fractures, shortening, and/or bowing of the long bones are found on prenatal ultrasound (Marini et al, 2017). When Osteogenesis imperfecta is suspected and/or molecularly confirmed in the prenatal period, families may be counseled that the diagnosis is lethal or severely life-limiting based on prenatal ultrasound observations and previously reported genotype-phenotype correlations (Yoshimura et al., 1996; Krakow et al., 2009). Ultrasound parameters for predicting lethality in skeletal dysplasias have been studied and include the chest-to-abdominal circumference ratio of <0.6 and femur length-to-abdominal circumference ratio of <0.16 (Yoshimura et al., 1996; Rahemtullah et al., 1997; Ramus et al., 1998). However, there are nuances to this strategy, for instance in cases where bowing deformities and fractures limit the accuracy of true femur length measurements (Milks et al., 2017). While genotype-phenotype correlations are also considered when predicting lethality, there can be a range of clinical variability even among those with the same genotype (Rauch et al., 2004, Marini et al, 2017). Some specialized delivery centers have reported on the accuracy of these methods in predicting lethality, yet many of the pregnancies evaluated are ultimately terminated, further limiting the ability to draw conclusions (Yeh et al., 2011). These limitations pose a challenge for perinatal providers counseling families on the diagnosis and attempting to prognosticate postnatal survival probability. Consequently, this information can cloud conversations surrounding delivery planning and influence access to potential life-saving therapies including invasive mechanical ventilation and feeding support. Advancements in medical technology and the option for life-sustaining interventions have significantly altered the prognoses for severely affected infants. In this manuscript, we describe perinatal outcomes of infants referred to a single specialized center after receiving a prior diagnosis of possibly lethal, lethal or type II OI where parents sought medical intervention after birth. We also outline advances in respiratory and feeding support needs, as well as length-of-stay for these neonates. The success of this multidisciplinary approach to neonatal OI care both challenges previously defined expectations for this patient population and offers a chance at survival.

MedicalResearch.com Interview with: [caption id="attachment_66982" align="alignleft" width="150"]Dr. lenka_vodstrcil Dr. Vodstrcil[/caption] Lenka Vodstrcil PhD Senior Research Fellow Deputy Head, Genital Microbiota and Mycoplasma Group President, Sexual Health Society of Victoria Associate Editor, Sexually Transmitted Infections School of Translational Medicine, FMNHS, Monash University Melbourne Sexual Health Centre, The Alfred Hospital Melbourne School of Population & Global Health, University of Melbourne [caption id="attachment_66983" align="alignleft" width="150"]STM - Catriona Bradshaw Dr. Bradshaw[/caption] Catriona Bradshaw MMBS(Hons), PhD, FAChSHM, FAHMS Professor (Research), Head of Research Translation and Mentorship and of The Genital Microbiota and Mycoplasma Group Melbourne School of Translational Medicine, Monash University and Alfred Hospital Principal Research Fellow at the Burnet Institute   MedicalResearch.com: What is the background for this study? Response: One in three women globally have bacterial vaginosis (BV), a condition that causes a malodourous discharge, and associated with serious gynaecologic and obstetric sequelae (including miscarriage and preterm birth) and increases the risk sexually transmitted infections (STIs) and HIV. Women with symptoms are treated with broad-spectrum antibiotics, however, over 50% of women experience BV recurrence within 3-6 months. The recurrence rate is even higher at 60-80% among women with an ongoing regular partner. Current practice is to simply retreat women experiencing BV recurrence with the same antibiotics, which leaves them (and clinicians) frustrated and distressed. We and others have accumulated a body of evidence to show that BV has the profile of an STI. BV-associated bacteria are detected in men in the distal urethra and on penile-skin, and couples share these organisms. However, to date, has not been recommended for BV as it is for other STIs. This is largely because men do not usually have any symptoms, and past partner-treatment trials in the 1980s and 1990s, which only used oral antibiotics for men, failed to prevent BV recurrence, which was taken as conclusive evidence against sexual transmission. Reviews of these trials have since identified their limitations. Given the evidence of male carriage of BV-associated bacteria at two genital sites, we hypothesised that both sites needed to be targeted with antimicrobial therapy to prevent re-infection post-treatment. The aim of our study was to assess if male partner-treatment concurrently with female treatment using a combination of oral and topical antibiotics for the first time, would decrease BV recurrence over 12 weeks compared to the current standard practice of treating women only.

MedicalResearch.com Interview with: Atharva Yeola, B.S. The Qualcomm Institute at UC San Diego MedicalResearch.com: What is the background for this study? Response: We initiated this study because, in the wake of the 2018 Murphy v. NCAA decision, sportsbooks began to proliferate at an unprecedented pace—expanding from a single state in 2017 to 38 states by early 2024. Accompanying that surge, the total amount bet on sports skyrocketed from $4.9 billion in 2017 to $121.1 billion in 2023, with 94% of wagers during 2023 occurring online. However, public health discussions lagged behind this explosive growth. We wanted to gauge whether this rapid adoption of sports betting, especially via easily accessible online platforms, was associated with increases in problem gambling and gambling addiction.

MedicalResearch.com Interview with: Jennifer Machado Soares Affiliation: University of São Paulo and Texas A&M University Institute of Physics of São Carlos, University of São Paulo, São Carlos, SP, Brazil. MedicalResearch.com: What is the background for this study? Response: Antibiotic treatments are becoming less effective due to the increasing prevalence of multidrug-resistant bacteria. Alternative treatments such as Antimicrobial photodynamic therapy (aPDT) have emerged and can act as an adjuvant to traditional antibiotic therapy. aPDT utilizes a photosensitizer activated by light to generate reactive oxygen species that can inactivate pathogens.

MedicalResearch.com Interview with: [caption id="attachment_66601" align="alignleft" width="200"]Slim Mzoughi, PhD Assistant Professor Icahn School of Medicine at Mount Sinai Department of Oncological Sciences Hess Center for Science and Medicine New York, NY 10029 Dr. Mzoughi[/caption] Slim Mzoughi, PhD Assistant Professor Icahn School of Medicine at Mount Sinai Department of Oncological Sciences Hess Center for Science and Medicine New York, NY 10029 MedicalResearch.com: What is the background for this study? Response: Resistance to current cancer treatments remains one of the biggest challenges in oncology, often leading to cancer recurrence even after patients appear to be in remission. To overcome this obstacle, we first need to understand the mechanisms behind this resistance. For a long time, treatment resistance in colorectal cancer (CRC)—the second deadliest cancer worldwide—has been attributed to a specific group of cells known as LGR5+ cancer stem cells. However, recent studies suggest that simply targeting these cells is insufficient for achieving long-term cancer control. That’s where our study comes in—to uncover why this is the case. MedicalResearch.com:  What are the main findings? Response:  Our study reveals that, early in tumor formation, LGR5+ cancer stem cells undergo molecular changes that render them unrecognizable. These changes cause them to resemble those found in the developing fetal intestine. In a way, this transformation reminds me of the legend of Edward Mordake, where these now fetal-like cells act as the “demon face” of cancer stem cells, resisting and surviving treatment. Crucially, we have identified the mechanism driving this reversion to a fetal-like state, which we term oncofetal-reprogramming. Excitingly, when we targeted the oncofetal cell state alongside existing chemotherapy treatments, this significantly enhanced treatment effectiveness and extended survival in preclinical models, offering new hope for CRC patients.